insulin degludec vs Insulin Efsitora Alfa

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

insulin degludec · Tresiba

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Partial signal

NCT00982644 · Phase 3 · completed

The trial was randomized and actively controlled, with 1,030 participants, but it was not blinded and its primary endpoint was the surrogate measure of change in HbA1c rather than a hard clinical outcome. HbA1c changed by -1.06% with insulin degludec versus -1.19% with insulin glargine, but no statistical comparison is reported, so whether the primary endpoint was met is unclear.

Next expected readout: June 2027 · NCT07173712 (registry estimate)

Reported efficacy

Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52); Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs) (Week 0 to Week 104 + 7 days of follow up): Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97) (unclear)

Result source: NCT00982644

Insulin Efsitora Alfa · Onswik

Marketed by Eli Lilly

Approved in Type 2 Diabetesprotein (Fc-fusion)
Partial signal

NCT05275400 · Phase 3 · completed

The study randomized 986 participants to efsitora or active-control insulin degludec, but treatment was open-label rather than blinded. The primary HbA1c noninferiority endpoint was met, with a treatment difference of -0.089 percentage points and a 95% confidence interval of -0.191 to 0.013 within the prespecified 0.4% margin; the primary endpoint was a surrogate measure.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545) (met)

Result source: NCT05662332

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin degludecInsulin Efsitora Alfa
HbA1c, change-1.1% vs -1.2%vs IGlaronce daily · wk 52 · n 773NCT00982644
22 other results
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · primary NCT02607306
  • -1.4% vs -1.6% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 167 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -1.3% vs -0.4% wk 26 · n 292 · Phase 3 · primary NCT01676116
  • -0.6% vs -0.5% wk 16 · n 143 · Phase 3 · primary NCT04588259
  • -0.1% vs -0.1% wk 16 · n 138 · Phase 3 · primary NCT01570751
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -0.9% vs -0.8% wk 104 · n 2431 · Phase 3 · secondary NCT01959529
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -0.5% vs -0.5% wk 88 · n 694 · Phase 3 · secondary NCT03078478
  • -0.9% vs -1.1% once daily · wk 104 · n 773 · Phase 3 · secondary NCT00982644
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
-1.3% vs -1.2%vs Insulin Degludecwk 52 · n 463NCT05362058
11 other results
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · primary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · primary NCT05275400
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.3% vs -1.2% wk 52 · n 463 · Phase 3 · secondary NCT05362058
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · secondary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · secondary NCT05275400
  • -1.4% vs -1.3% wk 26 · n 463 · Phase 3 · secondary NCT05362058
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -0.6% vs -0.7% wk 32 · n 130 · Phase 2 · primary NCT03736785
  • -0.6% vs -0.7% wk 32 · n 125 · Phase 2 · primary NCT03736785
  • -1.2% vs -1.3% wk 26 · n 127 · Phase 2 · primary NCT04450394
Body weight, change (kg)2.9 vs -1vs Liraglutidewk 52 · n 275NCT02607306
15 other results
  • 4.1 vs -1 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • 2.3 vs 2.8 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 0.2 vs -2.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • 2.9 vs 1.7 wk 88 · n 701 · Phase 3 · secondary NCT03078478
  • 1.2 vs 1.1 wk 16 · n 522 · Phase 3 · secondary NCT03268005
  • 1.3 vs -2.5 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 1.2 vs 3 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 2 vs -0.8 wk 26 · n 292 · Phase 3 · secondary NCT01676116
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
3.6 vs 3.5vs Insulin Degludecwk 52 · n 465NCT05362058
6 other results
  • 3.9 vs 3.3 wk 52 · n 357 · Phase 3 · secondary NCT05662332
  • 2.3 vs 2.2 500 U/mL · wk 78 · n 654 · Phase 3 · secondary NCT05275400
  • 3.2 vs 2.7 wk 26 · n 465 · Phase 3 · secondary NCT05362058
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • 1 vs 2 wk 32 · n 135 · Phase 2 · secondary NCT03736785
  • 1 vs 2 wk 32 · n 130 · Phase 2 · secondary NCT03736785
HbA1c below 7%75.3% vs 35.6%vs Liraglutide or Exenatidewk 26 · n 292NCT01676116—Not reported
Fasting plasma glucose, change-3.9 vs -3.7vs Insulin Glarginewk 104 · n 506NCT02501161
15 other results
  • -2.0 vs -1.4 wk 88 · n 685 · Phase 3 · secondary NCT03078478
  • -4.1 vs -2.6 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -4.0 vs -2.6 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -3.0 vs -3.0 wk 26 · n 290 · Phase 3 · secondary NCT04795531
  • -3.6 vs -1.9 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -3.0 vs -0.6 wk 26 · n 285 · Phase 3 · secondary NCT01676116
  • 0.6 vs 0.7 wk 16 · n 533 · Phase 3 · secondary NCT03268005
  • -3.5 vs -1.9 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 0.4 vs 0.2 wk 16 · n 143 · Phase 3 · secondary NCT04588259
  • -0.8 vs 0 wk 16 · n 128 · Phase 3 · secondary NCT01570751
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
—Not reported
3-point MACE (% with event)—Not posted · NCT05802862—Not reported

HbA1c, change

insulin degludec
-1.1% vs -1.2%vs IGlaronce daily · wk 52 · n 773NCT00982644
22 other results
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · primary NCT02607306
  • -1.4% vs -1.6% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 167 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -1.3% vs -0.4% wk 26 · n 292 · Phase 3 · primary NCT01676116
  • -0.6% vs -0.5% wk 16 · n 143 · Phase 3 · primary NCT04588259
  • -0.1% vs -0.1% wk 16 · n 138 · Phase 3 · primary NCT01570751
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -0.9% vs -0.8% wk 104 · n 2431 · Phase 3 · secondary NCT01959529
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -0.5% vs -0.5% wk 88 · n 694 · Phase 3 · secondary NCT03078478
  • -0.9% vs -1.1% once daily · wk 104 · n 773 · Phase 3 · secondary NCT00982644
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
Insulin Efsitora Alfa
-1.3% vs -1.2%vs Insulin Degludecwk 52 · n 463NCT05362058
11 other results
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · primary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · primary NCT05275400
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.3% vs -1.2% wk 52 · n 463 · Phase 3 · secondary NCT05362058
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · secondary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · secondary NCT05275400
  • -1.4% vs -1.3% wk 26 · n 463 · Phase 3 · secondary NCT05362058
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -0.6% vs -0.7% wk 32 · n 130 · Phase 2 · primary NCT03736785
  • -0.6% vs -0.7% wk 32 · n 125 · Phase 2 · primary NCT03736785
  • -1.2% vs -1.3% wk 26 · n 127 · Phase 2 · primary NCT04450394

Body weight, change (kg)

insulin degludec
2.9 vs -1vs Liraglutidewk 52 · n 275NCT02607306
15 other results
  • 4.1 vs -1 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • 2.3 vs 2.8 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 0.2 vs -2.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • 2.9 vs 1.7 wk 88 · n 701 · Phase 3 · secondary NCT03078478
  • 1.2 vs 1.1 wk 16 · n 522 · Phase 3 · secondary NCT03268005
  • 1.3 vs -2.5 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 1.2 vs 3 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 2 vs -0.8 wk 26 · n 292 · Phase 3 · secondary NCT01676116
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
Insulin Efsitora Alfa
3.6 vs 3.5vs Insulin Degludecwk 52 · n 465NCT05362058
6 other results
  • 3.9 vs 3.3 wk 52 · n 357 · Phase 3 · secondary NCT05662332
  • 2.3 vs 2.2 500 U/mL · wk 78 · n 654 · Phase 3 · secondary NCT05275400
  • 3.2 vs 2.7 wk 26 · n 465 · Phase 3 · secondary NCT05362058
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • 1 vs 2 wk 32 · n 135 · Phase 2 · secondary NCT03736785
  • 1 vs 2 wk 32 · n 130 · Phase 2 · secondary NCT03736785

HbA1c below 7%

insulin degludec
75.3% vs 35.6%vs Liraglutide or Exenatidewk 26 · n 292NCT01676116
Insulin Efsitora Alfa
—Not reported

Fasting plasma glucose, change

insulin degludec
-3.9 vs -3.7vs Insulin Glarginewk 104 · n 506NCT02501161
15 other results
  • -2.0 vs -1.4 wk 88 · n 685 · Phase 3 · secondary NCT03078478
  • -4.1 vs -2.6 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -4.0 vs -2.6 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -3.0 vs -3.0 wk 26 · n 290 · Phase 3 · secondary NCT04795531
  • -3.6 vs -1.9 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -3.0 vs -0.6 wk 26 · n 285 · Phase 3 · secondary NCT01676116
  • 0.6 vs 0.7 wk 16 · n 533 · Phase 3 · secondary NCT03268005
  • -3.5 vs -1.9 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 0.4 vs 0.2 wk 16 · n 143 · Phase 3 · secondary NCT04588259
  • -0.8 vs 0 wk 16 · n 128 · Phase 3 · secondary NCT01570751
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
Insulin Efsitora Alfa
—Not reported

3-point MACE (% with event)

insulin degludec
—Not posted · NCT05802862
Insulin Efsitora Alfa
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. insulin degludec: 5 of 5 rows · Insulin Efsitora Alfa: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin degludec
Rows use multiple source trials
Insulin Efsitora Alfa
Rows use multiple source trials
TRIM-D
absolute change · score
9.6 vs 7.3 Insulin Glargine score @ 26wka,b
NCT02501161 · Phase 3 · registry result, not featured evidence
10.03 vs 6.88 Insulin Degludec score @ 26wk500 U/mLa,b
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Dropout rate
21.5%once dailyc
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
2%
NCT01959529 · Phase 3
0%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
10.9%
NCT03336528 · Phase 4 · registry result, not featured evidence
—
NCT04588259 · Phase 3 · registry result, not featured evidence
2.7%
NCT04795531 · Phase 3 · registry result, not featured evidence
6.7%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
5.5%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
4%
NCT03175120 · Phase 3 · registry result, not featured evidence
—
NCT03078478 · Phase 3 · registry result, not featured evidence
2.7%
NCT03268005 · Phase 3 · registry result, not featured evidence
4.3%
NCT02501161 · Phase 3 · registry result, not featured evidence
2.2%
NCT02906917 · Phase 3 · registry result, not featured evidence
8.5%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
7.6%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
0%
NCT02911948 · Phase 3 · registry result, not featured evidence
4.8%
NCT02773368 · Phase 3 · registry result, not featured evidence
4.2%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
0.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
7.6%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
2.9%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
10.1%
NCT01952145 · Phase 3 · registry result, not featured evidence
5.5%Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—
NCT01570751 · Phase 3 · registry result, not featured evidence
9.5%500 U/mLd
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 8 more results
5.4%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Efsitora
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
8.8%Insulin Efsitora Alfa
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
4.7%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.8%LY3209590 Algorithm 1 (Paper)
NCT04450394 · Phase 2 · registry result, not featured evidence
0%LY3209590 Algorithm 2 (Digital)
NCT04450394 · Phase 2 · registry result, not featured evidence
12.6%LY3209590 Algorithm 1
NCT03736785 · Phase 2 · registry result, not featured evidence
12.9%LY3209590 Algorithm 2
NCT03736785 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
2.6%once dailyc
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
0%
NCT01959529 · Phase 3
—once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
—
NCT03336528 · Phase 4 · registry result, not featured evidence
—
NCT04588259 · Phase 3 · registry result, not featured evidence
—
NCT04795531 · Phase 3 · registry result, not featured evidence
0.6%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
1.4%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
0.7%
NCT03175120 · Phase 3 · registry result, not featured evidence
—
NCT03078478 · Phase 3 · registry result, not featured evidence
—
NCT03268005 · Phase 3 · registry result, not featured evidence
0.4%
NCT02501161 · Phase 3 · registry result, not featured evidence
0.4%
NCT02906917 · Phase 3 · registry result, not featured evidence
2.2%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
2.9%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
—
NCT02911948 · Phase 3 · registry result, not featured evidence
—
NCT02773368 · Phase 3 · registry result, not featured evidence
0.3%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
0.4%
NCT02420262 · Phase 3 · registry result, not featured evidence
0%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
1%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
2.9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
3.2%
NCT01952145 · Phase 3 · registry result, not featured evidence
0.3%Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—
NCT01570751 · Phase 3 · registry result, not featured evidence
1.1%500 U/mLd
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 8 more results
0.6%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Efsitora
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Insulin Efsitora Alfa
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.8%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.6%LY3209590 Algorithm 1 (Paper)
NCT04450394 · Phase 2 · registry result, not featured evidence
0%LY3209590 Algorithm 2 (Digital)
NCT04450394 · Phase 2 · registry result, not featured evidence
0.7%LY3209590 Algorithm 1
NCT03736785 · Phase 2 · registry result, not featured evidence
0.8%LY3209590 Algorithm 2
NCT03736785 · Phase 2 · registry result, not featured evidence
Serious AEs
15.1%once dailyc
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
38.6%
NCT01959529 · Phase 3
22.5%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
3.7%
NCT03336528 · Phase 4 · registry result, not featured evidence
6.7%
NCT04588259 · Phase 3 · registry result, not featured evidence
5.1%
NCT04795531 · Phase 3 · registry result, not featured evidence
4%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
3.9%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
4.3%
NCT03175120 · Phase 3 · registry result, not featured evidence
20.8%
NCT03078478 · Phase 3 · registry result, not featured evidence
7%
NCT03268005 · Phase 3 · registry result, not featured evidence
11.9%
NCT02501161 · Phase 3 · registry result, not featured evidence
6.8%
NCT02906917 · Phase 3 · registry result, not featured evidence
4.8%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
6.2%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
2.9%
NCT02911948 · Phase 3 · registry result, not featured evidence
2.9%
NCT02773368 · Phase 3 · registry result, not featured evidence
4.4%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
4.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
3.8%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
6.7%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
3.3%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
1.8%
NCT01952145 · Phase 3 · registry result, not featured evidence
—Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
3.1%Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
2.9%
NCT01570751 · Phase 3 · registry result, not featured evidence
15.7%500 U/mLd
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 8 more results
8.8%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
6.5%Efsitora
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Insulin Efsitora Alfa
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
6.8%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.7%LY3209590 Algorithm 1 (Paper)
NCT04450394 · Phase 2 · registry result, not featured evidence
7.1%LY3209590 Algorithm 2 (Digital)
NCT04450394 · Phase 2 · registry result, not featured evidence
5.2%LY3209590 Algorithm 1
NCT03736785 · Phase 2 · registry result, not featured evidence
6.1%LY3209590 Algorithm 2
NCT03736785 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
once dailyc
nasopharyngitis 23.9%
headache 13.8%
diarrhoea 10.8%
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 23 more results
once weekly
pain 17.5%
upper respiratory infection 0%
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
emergency room visit for bilateral knee pain 1.2%
emergency room visit for congestive heart failure 1.2%
emergency room visit for wound infection 1.2%
NCT03336528 · Phase 4 · registry result, not featured evidence
diabetic retinopathy 14.7%
hyperlipidaemia 14%
upper respiratory tract infection 9.3%
NCT04588259 · Phase 3 · registry result, not featured evidence
covid-19 4.8%
influenza 3.1%
diabetic retinopathy 2%
NCT04795531 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.7%
nasopharyngitis 5.1%
diabetic retinopathy 3.4%
NCT03172494 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 18.4%
diabetic retinopathy 7.8%
lipase increased 7.5%
NCT03172494 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 12.6%
lipase increased 12%
diabetic retinopathy 11.6%
NCT03175120 · Phase 3 · registry result, not featured evidence
nasopharyngitis 19%
upper respiratory tract infection 18.1%
diarrhoea 9%
NCT03078478 · Phase 3 · registry result, not featured evidence
nasopharyngitis 5.9%
NCT03268005 · Phase 3 · registry result, not featured evidence
headache 11.5%
nasopharyngitis 11.3%
diarrhoea 7.7%
NCT02501161 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13.6%
headache 10.2%
back pain 6%
NCT02906917 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 33.6%
weight increased 7%
pharyngitis 5.5%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 38.5%
constipation 9.8%
diabetic retinopathy 6.2%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 20%
diabetic retinopathy 16.2%
diarrhoea 14.3%
NCT02911948 · Phase 3 · registry result, not featured evidence
headache 8.6%
viral upper respiratory tract infection 7.7%
lipase increased 5.7%
NCT02773368 · Phase 3 · registry result, not featured evidence
BID
upper respiratory tract infection 21.1%
diabetic retinopathy 10%
viral upper respiratory tract infection 2.5%
NCT02762578 · Phase 3 · registry result, not featured evidence
nausea 11.1%
influenza 7.1%
diarrhoea 6.3%
NCT02420262 · Phase 3 · registry result, not featured evidence
twice daily
blood glucose decreased 35.4%
upper respiratory tract infection 6.2%
pyrexia 3.1%
NCT02648217 · Phase 3 · registry result, not featured evidence
nausea 5.2%
nasopharyngitis 4.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.2%
nausea 5.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
nausea 9.4%
diarrhoea 7.2%
vomiting 5%
NCT01952145 · Phase 3 · registry result, not featured evidence
lipase increased 10%
headache 9.3%
nasopharyngitis 8.9%
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 1.4%
NCT01570751 · Phase 3 · registry result, not featured evidence
500 U/mLd
covid-19 10.7%
nasopharyngitis 9.2%
dose calculation error 6.4%
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 7 more results
nasopharyngitis 9.2%
covid-19 7.9%
upper respiratory tract infection 7.9%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
influenza 7.3%
covid-19 5.3%
hypertension 5.3%
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 6.3%
influenza 3.8%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
anaemia 4.7%
arthralgia 2.3%
diarrhoea 2.3%
NCT04450394 · Phase 2 · registry result, not featured evidence
abdominal discomfort 7.1%
anaemia 7.1%
chest pain 7.1%
NCT04450394 · Phase 2 · registry result, not featured evidence
diarrhoea 6.7%
upper respiratory tract infection 5.9%
cough 0.7%
NCT03736785 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 10.6%
diarrhoea 6.1%
dizziness 5.3%
NCT03736785 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cPopulation comparability has not been reviewed for 25 of these studies.
  4. dPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin degludec

Time to First MACE 8.5% (n=3818) vs 9.3% (n=3819) Insulin Glargine
event count · % of participants
First EAC-confirmed MACE
NCT01959529 · Phase 3 · converted to % from 325 Participants as posted
Non-fatal MI 3.7% (n=3818) vs 4.3% (n=3819) Insulin Glargine
event count · % of participants
Myocardial infarction (non-fatal)
NCT01959529 · Phase 3 · converted to % from 143 Participants as posted
Stroke 1.8% (n=3818) vs 1.9% (n=3819) Insulin Glargine
responder rate · % of participants
Stroke (non-fatal)
NCT01959529 · Phase 3 · converted to % from 68 Participants as posted
CV Death 3% (n=3818) vs 3.1% (n=3819) Insulin Glargine
responder rate · % of participants
Cardiovascular death
NCT01959529 · Phase 3 · converted to % from 114 Participants as posted
Hypoglycemia Episodes Level 3 280 vs 472 Insulin Glargine count
event count · count
NCT01959529 · Phase 3
show 2 more results
2 vs 0 Insulin Icodec count @ 31wk
NCT04795531 · Phase 3 · registry result, not featured evidence
0 vs 0 Insulin Icodec count @ 26wk
NCT04795531 · Phase 3 · registry result, not featured evidence
Hypoglycemia Event Incidence 4.9% (n=3818) vs 6.6% (n=3819) Insulin Glargine
event rate · % of participants
NCT01959529 · Phase 3 · converted to % from 187 Participants as posted
HbA1c -0.5 vs 0 Insulin actual mean A1C change @ 26wkonce weekly
absolute change · actual mean A1C change
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
Daily Glucose mg/dL 9.98 vs 10.03 Glargine mmol/L @ 1wk
absolute value · mmol/L
Day 1 up to Day 10
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 179.75 mg/dL as posted
Daily Glucose mg/dL 8.71 vs 7.94 Glargine mmol/L @ 4wk
absolute value · mmol/L
Day after discharge up to the 4 week post-discharge study visit
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 157 mg/dL as posted
Daily Glucose mg/dL 8.25 vs 7.43 Glargine mmol/L @ 12wk
absolute value · mmol/L
4 week post-discharge up to the 12 week post-discharge study visit
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 148.7 mg/dL as posted
Clinically Significant Hypoglycemia Event Incidence 3.7% (n=82) vs 1.3% (n=79) Glargine
event rate · % of participants
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to % from 3 Participants as posted
Severe Hypoglycemia Event Incidence 0% (n=82) vs 0% (n=79) Glargine
event rate · % of participants
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted

+ 108 further endpoints in the CSV export.

Insulin Efsitora Alfa

Time in Range 61.37% (n=641) vs 60.95% (n=325) Insulin Degludec @ 26wk500 U/mL
absolute value · percentage points
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 3 more results
64.27% (n=387) vs 61.18% (n=381) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
66.12% (n=385) vs 65.85% (n=382) Insulin Degludec @ 26wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
58.39% (n=359) vs 57.05% (n=360) Insulin Glargine @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
Fasting Glucose Change mg/dL -30.97 vs -30.13 Insulin Degludec mg @ 26wk500 U/mL
absolute change · mg
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 4 more results
-46.76 vs -50.92 Glargine mg @ 52wk
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-30.87 vs -26.58 Insulin Glargine mg @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
-13.1 vs -31.5 Insulin Degludec mg @ 32wk
NCT03736785 · Phase 2 · registry result, not featured evidence
-18.6 vs -31.5 Insulin Degludec mg @ 32wk
NCT03736785 · Phase 2 · registry result, not featured evidence
Time Below Range 0.36 vs 0.22 Insulin Degludec % of time @ 26wk500 U/mL
absolute value · % of time
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
6.84 vs 5.25 Insulin Glargine % of time @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Above Range 37.25 vs 38.24 Insulin Degludec % of time @ 26wk500 U/mL
absolute value · % of time
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 4 more results
31.99 vs 32.4 Insulin Degludec % of time @ 12wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
28.93 vs 29.87 Insulin Degludec % of time @ 26wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
29.66 vs 33.05 Insulin Degludec % of time @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
40.1 vs 41.6 Insulin Glargine % of time @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
DTSQc - Treatment Satisfaction 14.9 vs 12.3 Insulin Degludec score @ 26wk500 U/mL
absolute value · score
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
15.1 vs 12.3 Insulin Degludec score @ 52wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.4 vs 11.7 Insulin Degludec score @ 78wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
FBG Change mg/dL -57.86 vs -63.04 Insulin Degludec mg @ 26wk
absolute change · mg
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
-59.77 vs -59.97 Insulin Degludec mg @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Glucose Variability CV 26.31% (n=368) vs 26.67% (n=360) Insulin Degludec @ 26wk
absolute value · percentage points
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
26.29% (n=368) vs 26.81% (n=360) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Below 70 mg/dL 1.06% (n=368) vs 0.93% (n=360) Insulin Degludec @ 12wk
absolute value · percentage points
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
1.55% (n=368) vs 1.25% (n=360) Insulin Degludec @ 26wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1.49% (n=368) vs 1.19% (n=360) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Below 54 mg/dL 0.24% (n=368) vs 0.27% (n=360) Insulin Degludec @ 12wk
absolute value · percentage points
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
0.33% (n=368) vs 0.28% (n=360) Insulin Degludec @ 26wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.32% (n=368) vs 0.3% (n=360) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Hypoglycemia Event Incidence 25.94% (n=397) vs 29.9% (n=398) Glargine @ 52wk
responder rate · % of participants
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Nocturnal Hypoglycemia Incidence 3.53% (n=397) vs 5.03% (n=398) Glargine @ 52wk
responder rate · % of participants
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
DTSQc - Treatment Satisfaction 15.1 vs 14.5 Glargine score @ 52wk
absolute value · score
Treatment satisfaction score
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3

+ 4 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin degludec's landscape · Insulin Efsitora Alfa's landscape